Pfizer (PFE) Profit After Tax (2009 - 2026)

Pfizer (PFE) has reported Profit After Tax for 18 consecutive years, with $2.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 9.32% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at $7.5 billion (down 49.2% YoY), while the FY2025 annual figure was $7.8 billion, down 3.48% from the prior year.
• Profit After Tax advanced to $2.7 billion in Q1 2026 per PFE's latest filing, from -$1.7 billion in the prior quarter.
• Across five years, Profit After Tax topped out at $9.9 billion in Q3 2022 and bottomed at -$1.7 billion in Q4 2025.
• Historically, Profit After Tax has averaged $2.9 billion across 5 years, with a median of $2.8 billion in 2025.
• Annual changes were most pronounced in 2023 — Profit After Tax tumbled 96.15% — and 2024, when it surged 520.63%.
• Pfizer's Profit After Tax stood at $211.0 million in 2022, then slumped by 71.56% to $60.0 million in 2023, then soared by 12640.0% to $7.6 billion in 2024, then tumbled by 121.66% to -$1.7 billion in 2025, then soared by 262.8% to $2.7 billion in 2026.
• Business Quant data shows PFE's Profit After Tax at $2.7 billion in Q1 2026, -$1.7 billion in Q4 2025, and $3.6 billion in Q3 2025.